Beaumont Community Clinical Oncology Program

博蒙特社区临床肿瘤学计划

基本信息

批准号：
7664465
负责人：
Gary William Chmielewski
金额：
$ 74.96万
依托单位：
WILLIAM BEAUMONT HOSPITAL RESEARCH INST
依托单位国家：
美国
项目类别：
财政年份：
2002
资助国家：
美国
起止时间：
2002-06-27 至 2010-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7664465
关键词：
Agreement Area Arts Beds Breast Cancer Control Cancer Control Research Cancer Prevention Trial Caring Chest Clinical Research Clinical Trials Colon Carcinoma Communities Community Clinical Oncology Program Controlled Clinical Trials Controlled Study County Credentialing Data Collection Development Diagnosis Disease Early Diagnosis Education Ensure Funding General Population Genus Cola Goals Gynecology Health Hospitals Incidence Individual Institution Life Malignant Neoplasms Michigan Morbidity - disease rate National Surgical Adjuvant Breast and Bowel Project Oncology Group Operative Surgical Procedures Participant Patients Performance Pharmacy facility Physicians Population Prevention therapy Primary Care Physician Process Prostate Cancer Prevention Trial Protocols documentation Quality Control Radiation Therapy Oncology Group Recording of previous events Recruitment Activity Research Research Ethics Committees Research Personnel Research Support Review Committee Secondary Prevention Southwest Oncology Group Specialist System Technology Underrepresented Minority Universities Woman base cancer prevention experience improved interest leukemia/lymphoma medical specialties men mortality oncology programs rectal rehabilitation management standard of care suburb treatment trial

项目摘要

DESCRIPTION (provided by applicant): William Beaumont Hospital (WBH) located in the northwest Detroit suburb of Royal Oak, Michigan (1091 beds) and in the rapidly growing suburb of Troy, Michigan (242-beds, approximately twelve miles northeast of Royal Oak), continues to be a highly productive contributor to the NCI's Community Clinical Oncology Program. Against the diverse demographic backdrop of Oakland and Macomb Counties (combined population exceeding 2 million) and WBH's history of diagnosing over 4,000 new cancer cases per year, the Beaumont CCOP (BCCOP) is able to offer 110 multi-disciplinary investigators in 20 specialty departments. This includes a strong surgical component as witnessed by the accrual performance achieved during the past two years of our being designated a CCOP. In our first year with the CCOP (2002-03) we were able to accumulate an aggressive 151.3 treatment and 178.6 control credits, for a grand total of 329.9 credits. In our second year as a CCOP (2003-04), with our focus on cancer control, we accumulated an impressive 288.4 control and 99.2 treatment credits, totaling 387.6 strong. Current results indicate that in our third year (2004-05) we anticipate to accrue 190.1 treatment and a noteworthy 374.7 control credits, arriving at an estimated combined total of 563.8 The continuing goals of the BCCOP include increasing the accrual of patients to treatment trials, carefully following patients and participants currently on study, and to further build our cancer control capabilities. The specific aims of the program are to reduce cancer incidence, morbidity, and mortality by accelerating the transfer of newly developed cancer prevention therapies, to improve early detection rates, and to facilitate patient treatment management, rehabilitation, and the dissemination of scientific results to the profession and to the general public. To ensure that we achieve quality results through the scientific process, we utilize a centralized research support approach through an established Cancer Clinical Trials office (CCTO), an experienced Institutional Review Board (IRB), a credentialed pharmacy staff, a Protocol Review Committee (PRC), and a Steering Committee commissioned to guide and supervise the activities of BCCOP. The Beaumont CCOP bases all activities on our motto: "Today's clinical trial for tomorrow's standard of care."

描述（由申请人提供）：威廉·博蒙特医院（WBH）位于密歇根州皇家橡树皇家橡树（1091张床）以及密歇根州特洛伊（Troy）的迅速发展的郊区（242张床，皇家橡树（Royal Oak）东北约十二英里）中，这是对NCI的社区联合会学计划的富有成效的贡献。 Beaumont CCOP（BCCOP）能够在20个专业部门提供110个多学科研究人员，在奥克兰和莫克姆县的各种人口背景下（超过200万人）和WBH诊断4,000多个新癌症病例的历史。这包括一个强大的手术组件，这是我们被指定为CCOP的过去两年中所获得的应计性能所证明的。在CCOP（2002-03）的第一年，我们能够积累积极的151.3治疗和178.6个控制学分，总计329.9个学分。在我们担任CCOP的第二年（2003-04）中，我们着重于癌症控制，我们积累了令人印象深刻的288.4控制和99.2治疗学分，总计387.6强。目前的结果表明，在我们的第三年（2004 - 05年）中，我们预计将获得190.1治疗和值得注意的374.7控制学分，到达估计总计563.8 BCCOP的持续目标总计563.8，包括将患者的应计为治疗试验，仔细研究患者和参与者，并在研究中仔细地进行研究，以进一步构建我们的癌症Cabsab。该计划的具体目的是通过加速新开发的癌症预防疗法的转移，提高早期检测率，并促进患者治疗的管理，康复以及将科学结果传播给该行业以及向专业和公众传播，从而降低癌症的发病率，发病率和死亡率。为了确保我们通过科学过程实现质量结果，我们通过既定的癌症临床试验办公室（CCTO），经验丰富的机构审查委员会（IRB），证书的药房，协议审查委员会（PRC）和指导委员会委托指导和监督BCCOP的活动。 Beaumont CCOP以我们的座右铭为基础：“今天的明天护理标准的临床试验”。